Health and Me

Tanya Dutt

In 'First-Of-A-Kind' Surgery Man Lives For 100 Days With Artificial Heart Made Of Titanium

In 'First-of-a-Kind' Surgery Man Lives For 100 Days With Artificial Heart Made Of Titanium

In a revolutionary medical achievement, an Australian man with end-stage heart failure became the first person in the world to walk out of a hospital after undergoing a total <span>artificial heart</span> implant. The pioneering surgery, performed at Sydney's St. Vincent's Hospital, is a significant breakthrough in cardiology, providing hope for thousands of patients globally on the waiting list for heart transplants.

The patient, a 40-year-old man who wished to be unidentified, spent more than 100 days with the artificial heart before undergoing a donor <span>heart transplant</span> in early March. This historic success supports the promise of the BiVACOR Total Artificial Heart (TAH) as an alternative for long-term replacement for people with advanced heart failure.

Created by Dr. Daniel Timms, the BiVACOR TAH is a groundbreaking medical device designed to replace a failing human heart entirely. In contrast to conventional heart pumps that augment the heart's work, this device fully assumes the function of both ventricles and provides a constant and regulated flow of blood.

One of the most important technological advancements of the <span>BiVACOR heart</span> is its application of magnetic levitation. The machine has a single mobile component—a rotor that is kept suspended by magnets, doing away with mechanical bearings or valves that might break down with time. This not only increases durability but also replicates the natural rhythm of the human heart, providing perfect circulation to the body and lungs.

Cardiovascular diseases are the primary killer of humans worldwide and account for about 18 million deaths annually, states the World Health Organization. Heart failure, usually a complication of diseases like coronary artery disease, heart attack, and diabetes, makes the heart so weak it cannot pump blood effectively anymore.

For end-stage biventricular heart failure patients, donor transplants are their sole chance of survival. Alas, donor hearts are always in short supply compared to the demand. Within the United States alone, nearly 3,500 heart transplants were completed in 2024, with 4,400 new additions to the waiting list. That gap leaves thousands of patients with no viable chance of treatment and underscores the desperate need for such alternatives as artificial hearts.

<h2>Is This A Step Towards a Future Without Donor Dependency?</h2>

The BiVACOR TAH is still in the initial clinical trials, but its success to date seems to hold hope for future patients with serious heart disease. The recent Australian patient's case is the longest recorded survival time of a patient with the device, demonstrating its potential for sustaining a patient until they can receive a viable donor heart.

Victor Chang Cardiac Research Institute Professor Chris Hayward, who guided the recovery of the Australian patient, termed the advancement "a whole new ball game for heart transplants." According to him, within the next ten years, artificial hearts might be a practical option for patients who cannot be provided with a donor heart in time.

Though the Australian case is a milestone, the BiVACOR device has also been under trial elsewhere in the world. The U.S. Food and Drug Administration's Early Feasibility Study has already witnessed five patients getting the artificial heart implanted successfully. The first of these trials was conducted in July 2023, when a 58-year-old man at the Texas Medical Center got the implant. While he lived for just eight days before the transplant with a donor heart, the trial showed the device was capable of keeping critically ill patients alive.

Clinical trials will grow to 15 patients, with further tests on the device's safety and efficacy. Meanwhile, Monash University's Artificial Heart Frontiers Program, an AU$50 million ($31 million) project, is in full swing developing and commercializing three devices to treat heart failure, including the BiVACOR TAH.

<h2>Implications for the Future of <span rel="noindex">Heart Failure Treatment</span></h2>

Successful use of the BiVACOR artificial heart has the potential to change the management of heart failure around the globe. For those not a candidate for heart transplants or with prolonged waiting lists, this technology represents a new hope. In contrast to mechanical pumps that merely supplement failing hearts, an entirely operational artificial heart might change survival rates and quality of life for thousands of patients.

Although more studies are required prior to widespread usage, the Australian breakthrough is an important milestone in the direction of a future when artificial hearts will be a normal treatment. The more technology is developed and more clinical trials that are conducted, the closer one comes to achieving the dream of replacing a defective human heart with a long-lasting, life-extending device.

Health Conditions A-Z

health

heart health

artificial heart

bivacor heart

heart transplant

heart failure treatment

cardiovascular disease

medical breakthrough

heart implant

Do You Have A Cancer Gene? Here’s What You Need To Do Next

7 Daily Exercises That Can Strengthen Your Back

UK Government Scraps NHS England: What It Means And Why It Matters

Health News

10 Foods That Raise Uric Acid Levels

10 Desk Exercises To Keep You Active

10 Exercises To Help You Do Push-Ups Properly

10 Home Exercises For Core Strength

10 Exercises To Help You Relieve Back Pain

10 Low-Sodium Dinner Options You Must Try

10 Health Benefits Of Star Anise

10 Ways To Recover Quickly After Working Out

10 Low-Sodium Healthy Heart Snack

10 Bedtime Habits To Help You Lose Weight

10 Low Carb Lunch Options You Must Try

10 Foods to Avoid Eating During Season

10 Strength Exercises To Help You Burn Belly Fat

10 Food Habits That Are Ruining Your Health

10 Exercises You Should Do For Better Joint Health

10 Foods That Are High-Protein You May Not Know About

10 Fiber Rich Dinner Choices To Try

10 Ways To Curb Unhealthy Cravings

10 Healthy Egg Recipes You Can Try

​10 Morning Exercises You Should Do Everyday​

10 Protein Healthy Bread Recipes

10 Morning Habit You Should Teach Children

10 Nutty Recipes You Should Try For Your Health

10 Exercises You Should Do Before Sleeping

10 Exercises You Should Do For Arm Strength

10 Ways You Can Maximize Your Gym Exercises

10 Exercises You Can Do While Walking

10 Healthy Savoury Pancakes To Have For Breakfast

10 Herbal Tea Mixes For Winters

10 Habits To Ensure Your Teeth Health

10 Detox Juices You Should Try

10 Low Impact Exercises For Weight Loss

10 Foods That Should Be Part Of A Runners Diet

10 Gym Exercises Basketball Players Should Do

10 Light Foods You Can Eat Before Exercises

10 Ways To Beat The Sleep Spell In Office

10 Tips To Help Muscle Recovery

6-6-6 Walking Routine Can Help You Stay Fit

10 Breathing Exercises To Try When You’re Feeling Anxious

10 Ways To Beat Morning Fatigue

In a revolutionary medical achievement, an Australian man with end-stage heart failure became the first person in the world to walk out of a hospital after undergoing a total artificial heart implant. The pioneering surgery, performed at Sydney's St. Vincent's Hospital, is a significant breakthrough in cardiology, providing hope for thousands of patients globally on the waiting list for heart transplants.The patient, a 40-year-old man who wished to be unidentified, spent more than 100 days with the artificial heart before undergoing a donor heart transplant in early March. This historic success supports the promise of the BiVACOR Total Artificial Heart (TAH) as an alternative for long-term replacement for people with advanced heart failure.Created by Dr. Daniel Timms, the BiVACOR TAH is a groundbreaking medical device designed to replace a failing human heart entirely. In contrast to conventional heart pumps that augment the heart's work, this device fully assumes the function of both ventricles and provides a constant and regulated flow of blood.One of the most important technological advancements of the BiVACOR heart is its application of magnetic levitation. The machine has a single mobile component—a rotor that is kept suspended by magnets, doing away with mechanical bearings or valves that might break down with time. This not only increases durability but also replicates the natural rhythm of the human heart, providing perfect circulation to the body and lungs.Cardiovascular diseases are the primary killer of humans worldwide and account for about 18 million deaths annually, states the World Health Organization. Heart failure, usually a complication of diseases like coronary artery disease, heart attack, and diabetes, makes the heart so weak it cannot pump blood effectively anymore.For end-stage biventricular heart failure patients, donor transplants are their sole chance of survival. Alas, donor hearts are always in short supply compared to the demand. Within the United States alone, nearly 3,500 heart transplants were completed in 2024, with 4,400 new additions to the waiting list. That gap leaves thousands of patients with no viable chance of treatment and underscores the desperate need for such alternatives as artificial hearts.Is This A Step Towards a Future Without Donor Dependency?The BiVACOR TAH is still in the initial clinical trials, but its success to date seems to hold hope for future patients with serious heart disease. The recent Australian patient's case is the longest recorded survival time of a patient with the device, demonstrating its potential for sustaining a patient until they can receive a viable donor heart.Victor Chang Cardiac Research Institute Professor Chris Hayward, who guided the recovery of the Australian patient, termed the advancement "a whole new ball game for heart transplants." According to him, within the next ten years, artificial hearts might be a practical option for patients who cannot be provided with a donor heart in time.Though the Australian case is a milestone, the BiVACOR device has also been under trial elsewhere in the world. The U.S. Food and Drug Administration's Early Feasibility Study has already witnessed five patients getting the artificial heart implanted successfully. The first of these trials was conducted in July 2023, when a 58-year-old man at the Texas Medical Center got the implant. While he lived for just eight days before the transplant with a donor heart, the trial showed the device was capable of keeping critically ill patients alive.Clinical trials will grow to 15 patients, with further tests on the device's safety and efficacy. Meanwhile, Monash University's Artificial Heart Frontiers Program, an AU$50 million ($31 million) project, is in full swing developing and commercializing three devices to treat heart failure, including the BiVACOR TAH.Implications for the Future of Heart Failure TreatmentSuccessful use of the BiVACOR artificial heart has the potential to change the management of heart failure around the globe. For those not a candidate for heart transplants or with prolonged waiting lists, this technology represents a new hope. In contrast to mechanical pumps that merely supplement failing hearts, an entirely operational artificial heart might change survival rates and quality of life for thousands of patients.Although more studies are required prior to widespread usage, the Australian breakthrough is an important milestone in the direction of a future when artificial hearts will be a normal treatment. The more technology is developed and more clinical trials that are conducted, the closer one comes to achieving the dream of replacing a defective human heart with a long-lasting, life-extending device.